



Agenda: July 15, 2025



**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**  
**NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.**  
Tuesday, July 15, 2025  
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
<a href="#">Join the meeting now</a>  Meeting ID: 225 141 803 542 Passcode: nP249PC2  <a href="#">Download Teams</a>   <a href="#">Join on the web</a>	+1-858-252-2734 (US Toll)  Phone Conference ID: 991 316 184#

## **AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of January 2025 Meeting Minutes
  - b. Approval of April 2025 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be Reviewed as Single Products:
    - i. Zunveyl® (*Alzheimer's Agents*)
    - ii. Qfitlia™ (*Non-PDL*)
    - iii. Ryzneuta® (*Colony Stimulating Factors*)
    - iv. Vanrafia® (*Non-PDL*)
- V. New Therapeutic Class**
  - a. Antimigraine Agents, CGRP Inhibitors & Other Agents: Acute Treatment
  - b. Antimigraine Agents, CGRP Inhibitors & Other Agents: Prophylaxis
    - a. Injectable
    - b. Oral
- VI. Therapeutic Classes with Recommended Changes**
  - a. Bladder Relaxants
  - b. Narcolepsy Agents
  - c. Skeletal Muscle Relaxants
  - d. Stimulants & Related Agents
  - e. Glucagon Agents



**VII. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"><li>• Angiotensin-Converting Enzyme (ACE) Inhibitors</li><li>• ACEI + Diuretic Combinations</li><li>• Angiotensin Modulator + Calcium Channel Blocker (CCB) Combinations</li><li>• Angiotensin Receptor Blockers (ARBs)</li><li>• Antianginal &amp; Anti-Ischemic</li><li>• Antiarrhythmics, Oral</li><li>• Anticoagulants</li><li>• ARB + Diuretic Combinations</li><li>• Beta-Blockers</li><li>• Calcium Channel Blockers (CCBs)</li><li>• Direct Renin Inhibitors</li><li>• Lipotropics, Other</li><li>• Lipotropics, Statins</li><li>• PAH Agents – Oral and Inhaled</li><li>• Platelet Aggregation Inhibitors</li><li>• Alzheimer's Agents</li><li>• Anticonvulsants</li><li>• Antidepressants, Monoamine Oxidase Inhibitors</li><li>• Antidepressants, Other</li><li>• Antidepressants, SNRIs</li></ul>	<ul style="list-style-type: none"><li>• Antidepressants, SSRIs</li><li>• Antidepressants, Tricyclics</li><li>• Antimigraine Agents, CGRP Inhibitors &amp; Other Agents: Acute Treatment</li><li>• Antimigraine Agents, CGRP Inhibitors &amp; Other Agents: Prophylaxis - Injectable</li><li>• Antimigraine Agents, CGRP Inhibitors &amp; Other Agents: Prophylaxis - Oral</li><li>• Antimigraine Agents - Triptans</li><li>• Antiparkinson's Agents</li><li>• Antipsychotics, First Generation</li><li>• Antipsychotics, Second Generation: Oral and Injectable</li><li>• Anxiolytics</li><li>• Dopamine Receptor Agonists</li><li>• Movement Disorders</li><li>• Neuropathic Pain</li><li>• Sedative Hypnotics</li><li>• Tobacco Cessation Products</li><li>• 5-Alpha Reductase Inhibitors</li><li>• Alpha Blockers For Benign Prostatic Hyperplasia (BPH)</li></ul>
---	---

**VIII. Adjournment**

- a. Schedule of Upcoming Meetings  
i. **October 14, 2025**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.